Skye Bioscience, Inc.
SKYE
$1.11
-$0.10-8.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.02% | -14.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.29% | 55.14% | |||
| Operating Income | 27.29% | -55.14% | |||
| Income Before Tax | 27.62% | -58.73% | |||
| Income Tax Expenses | -- | 70.00% | |||
| Earnings from Continuing Operations | 27.63% | -58.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.63% | -58.74% | |||
| EBIT | 27.29% | -55.14% | |||
| EBITDA | 27.53% | -55.90% | |||
| EPS Basic | 27.63% | -58.71% | |||
| Normalized Basic EPS | 27.48% | -59.49% | |||
| EPS Diluted | 27.63% | -58.71% | |||
| Normalized Diluted EPS | 27.48% | -59.49% | |||
| Average Basic Shares Outstanding | 0.02% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||